RhumbLine Advisers
ACHV icon

RhumbLine Advisers’s Achieve Life Sciences ACHV Stock Holding History

RhumbLine Advisers’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,267
Closed -$113K – 4140
2025
Q1 		$113K Buy
42,267
+1,497
+4% +$4.66K ﹤0.01% 3352
2024
Q4 		$144K Sell
40,770
-196
-0.5% -$888 ﹤0.01% 3357
2024
Q3 		$194K Sell
40,966
-852
-2% -$3.89K ﹤0.01% 3258
2024
Q2 		$197K Buy
+41,818
New +$201K ﹤0.01% 3232
2014
Q2 		– Sell
-6
Closed -$148K – 3008
2014
Q1 		$148K Hold
6
– – ﹤0.01% 2859
2013
Q4 		$111K Hold
6
– – ﹤0.01% 2946
2013
Q3 		$123K Hold
6
– – ﹤0.01% 2908
2013
Q2 		$132K Buy
+6
New +$134K ﹤0.01% 3169

Other funds holding ACHV

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's ACHV Position: Q2 2025 in Review

RhumbLine Advisers sold out of Achieve Life Sciences (ACHV) in Q2 2025, closing a stake of 42,267 shares — an estimated $113K sold.

RhumbLine Advisers first reported a position in ACHV in Q2 2013 and held it in 8 quarters. The position peaked at $197K in Q2 2024. 65 funds tracked by Wall St. Rank hold ACHV as of Q2 2025.

  • RhumbLine Advisers reported no remaining Achieve Life Sciences position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 42,267 Achieve Life Sciences shares in Q2 2025, an estimated $113K.
  • RhumbLine Advisers first reported a position in Achieve Life Sciences in Q2 2013 and held it in 8 quarters.
  • RhumbLine Advisers's Achieve Life Sciences position peaked at $197K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.